Whole blood RNA sequencing of African American kidney transplant recipients from VericiDx cohort. Whole blood RNA sequencing of African American kidney transplant recipients from VericiDx cohort

The VericiDx cohort is an ongoing clinical trial (241 patients (32.0% self-reported AA) enrolled as of 06/30/2023) with a focus on predicting early acute rejection and renal fibrosis post-transplantation (ClinicalTrials.gov: NCT04727788). Overall design: Pretransplant RNA sequencing profiles (101 PE reads) were generated on pretransplant blood, with a subset of 77 recipients. The RNA data in these 77 AA recipients was combined with two cohorts to identify the meta-gene signatures associated with the LILRB3-4SNPs. The LILRB3-4SNPs was correlated with early eGFR values (within two years) in meta-analysis with other three cohorts. However, the relatively short follow-up duration for many patients in this cohort limited the association analysis for graft failure.